Dengue virus (DENV) causes several hundred million human infections and more than 20,000 deaths annually. Neither an efficacious vaccine conferring immunity against all four circulating serotypes nor specific drugs are currently available to treat this emerging global disease. Capping of the DENV RNA genome is an essential structural modification that protects the RNA from degradation by 5′ exoribonucleases, ensures efficient expression of viral proteins, and allows escape from the host innate immune response. The large flavivirus nonstructural protein 5 (NS5) (105 kDa) has RNA methyltransferase activities at its N-terminal region, which is responsible for capping the virus RNA genome. The methyl transfer reactions are thought to occur sequentially using the strictly conserved flavivirus 5′ RNA sequence as substrate (G ppp AG-RNA), leading to the formation of the 5′ RNA cap:To elucidate how viral RNA is specifically recognized and methylated, we determined the crystal structure of a ternary complex between the full-length NS5 protein from dengue virus, an octameric cap-0 viral RNA substrate bearing the authentic DENV genomic sequence (5′-m7 G 0ppp A 1 G 2 U 3 U 4 G 5 U 6 U 7 -3′), and S-adenosyl-L-homocysteine (SAH), the by-product of the methylation reaction. The structure provides for the first time, to our knowledge, a molecular basis for specific adenosine 2′-O-methylation, rationalizes mutagenesis studies targeting the K61-D146-K180-E216 enzymatic tetrad as well as residues lining the RNA binding groove, and offers previously unidentified mechanistic and evolutionary insights into cap-1 formation by NS5, which underlies innate immunity evasion by flaviviruses.dengue virus | nonstructural protein 5 methyltransferase-polymerase | 2′-O-ribose methyltransferase | cap-0 RNA | innate immunity evasion S everal members of the Flavivirus genus from the Flaviviridae family are major human pathogens, such as the four serotypes of dengue virus (DENV1-4), West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV). Recent largescale DENV vaccine trials using a tetravalent formulation and three dose injections have shown only limited protection against the four DENV serotypes, and no specific antiviral drug has reached the market so far (1-3). The flavivirus genome consists of a (+)-sense singlestranded RNA of ∼11 kb with a type 1 cap structure, followed by the strictly conserved dinucleotide sequence "AG": 5′-m7 G ppp A m2′-O-G-3′ (4, 5). Addition of the cap moiety to the 5′ end of the viral genome is crucial for viral replication, because this structure ensures efficient production of viral polyproteins by the host translation machinery and protection against degradation by 5′-3′ exoribonucleases, and also because it conceals the triphosphorylated (or diphosphorylated) end from recognition by host cell innate immune sensors (6-9). Following (+)-strand RNA synthesis by the C-terminal RNA-dependent RNA polymerase (RdRp) domain of nonstructural protein 5 (NS5), cap formation in flaviviruses resu...